NEW YORK / Mar 04, 2024 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024 at approximately 3:05 p.m. Eastern Daylight Time (EDT).
To listen to a live webcast of the event, please visit MultiPlan’s website at https://investors.multiplan.us/events-and-presentations/default.aspx at least 15 minutes prior to the event to download and install any necessary audio software. Individuals who listen to the event will be presumed to have read MultiPlan’s recent filings with the Securities and Exchange Commission. Following the presentation, a webcast replay will be available for 30 days.
About MultiPlan
MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based, and data and decision science services. MultiPlan is a trusted partner to over 700 healthcare payors, brokers, employer groups, and supplemental carriers in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.
| Last Trade: | US$29.20 |
| Daily Volume: | 0 |
| Market Cap: | US$472.160M |
November 12, 2025 November 07, 2025 October 08, 2025 August 06, 2025 July 08, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load